Millions inherit deafness from SLC26A4 mutations. In Asia, these mutations are common triggers for severe-to-profound hearing loss. The condition destroys sensory hair cells and swells inner-ear fluid cavities.
Gene therapy could fix the root cause. But interventions were restricted to the embryonic stage, imposing steep ethical and practical hurdles.
Why it matters
Researchers delivered the therapy after birth. It worked.
- The team used a synthetic gene vector engineered to target fluid-regulating tissues in the inner ear.
- They injected the Slc26a4 gene into a mouse model during early neonatal and juvenile stages.
- The cochlea responded efficiently to the therapeutic gene.
- Hearing thresholds dropped. Sensory hair cells survived. Inner ear fluid cavity swelling reversed into adulthood.
How it works
The vector restored a missing protein that stabilizes the inner ear's electrochemical environment.
- Delivery during juvenile stages proved successful.
- Early intervention produced the best outcomes.
- Juvenile-stage success means established pathology can still be reversed.
The intrigue
The therapeutic window is wider than assumed, shifting the outlook from in-utero prevention to postnatal correction.
"The inner ear remains receptive to structural and functional rescue." —co-corresponding author Yen-Fu Cheng, MD, National Yang Ming Chiao Tung University's Institute of Brain Science.
The bottom line
The barrier to conducting human trials has greatly lowered. Dr. Chen-Chi Wu, co-corresponding author and otolaryngology professor at National Taiwan University, called it a "realistic, translationally relevant platform to prevent progressive deafness."
